

ALLENEX AB (PUBL)

YEAR-END REPORT 2014

For the period October- December

- Net sales for the period amounted to SEK 30.7 million (29.4).
- Operating income (EBIT) for the period was SEK 9.5 million (2.2).
- Operating margin for the period was 31 percent (8).
- Earnings after tax for the period rose to SEK 7.2 million (0.1).
- Earnings per share for the period, basic and diluted, was SEK 0.05 (0.02).

For the period January-December

- Net sales for the year amounted to SEK 125.2 million (111.8).
- Operating income (EBIT) for the year was SEK 22.9 million (9.6).
- Operating margin for the year was 18 percent (9).
- Earnings after tax for the year increased to SEK 15.2 million (2.3).
- Earnings per share for the year, basic and diluted, was SEK 0.11 (0.05).

President and CEO Anders Karlsson's commentary on 2014:

"In 2014, we worked successfully to improve our margins, and we report an operating margin of 18 percent for 2014 compared to 9 percent for 2013. We ended the year on a strong note, with an EBIT result of SEK 9.5 million in the fourth quarter. Turnover for 2014 as a whole increased by 12 percent, with stable growth in all product groups. Net sales growth was generated both in our established core markets in Europe and the USA, as well as from rising sales in new markets. Both sales and results also benefited from a weaker Swedish krona. We are now entering 2015 with a strong momentum and look forward to the launch of real-time PCR, a new platform for HLA typing, planned for the second half of the year."

For more information please contact:

Anders Karlsson, CEO, tel: +46 (0) 70-918 00 10 or email: anders.karlsson@allenex.se


Yvonne Axelsson, CFO, tel: +46 (8) 508 939 72 or email: yvonne.axelsson@allenex.se

GROUP PERFORMANCE


Allenex is a life science company that develops, manufactures, markets and sells products on the global market that facilitate safer transplantation of blood stem cells and organs. Allenex is listed on NASDAQ Stockholm, Small Cap, (ticker: ALNX). There are 55 employees in the Allenex group.

SALES

Net sales for the fourth quarter were SEK 30.7 million (29.4), corresponding to an increase of 4 percent compared to the same period last year.



Sales in North America increased in the local currency (USD) by 10 percent during the fourth quarter, compared to the same period last year, equivalent to 27.8 percent of total sales in SEK (full-year 2014 23.0 percent). After three strong quarters, sales in Europe grew by 3 percent in the local currency (EUR) during the fourth quarter compared to the same period last year. Sales in Allenex three largest European markets continue to be strong. In 2014, sales in Italy grew by 7.5 percent, France by 13.7 percent, while sales in Germany declined by 4 percent, primarily due to the transplantation scandal that arose in 2013, which still has a negative impact on the number of organ transplants in the country.



North Africa and the Middle East also saw an increase in demand for Allenex products. In recent years in this region, Allenex has established connections with a number of well-known local distributors and is now seeing the positive

effect on sales of Allenex products, particularly in the SSP segment, in countries such as Egypt, Algeria, Jordan, Iran and Pakistan. In these countries there is also a growing interest in SBT technology and Allenex also expects demand for these products to grow in the coming years.

Allenex products are distributed via direct sales through a proprietary sales organization in key markets such as the USA, Germany and in the Nordic region. They are also distributed via partnerships with local distributors in other markets. Registration processes are ongoing for the company's products in China and Brazil, among other countries, with work underway to secure strong local sales/distribution partners in these markets. .

CUSTOMER GROUPS

Allenex customers largely constitute laboratories active in transplantation diagnostics. Today, there are three different technologies on the market for HLA typing (SSP, SSO and SBT), where the most common typing technique globally, in terms of volume, is SSO. However, most laboratories use SSP typing, either as a primary or complementary technique. The size of the laboratory and its level of automation determines to what extent the respective technologies are used. Today, the largest laboratories mainly utilize automated solutions (SBT and SSO) as their primary technology, while smaller laboratories generally prefer SSP typing. Subsequently, the choice of typing technology is a key parameter for customer categorization.

All large Allenex competitors offering automated SSO or SBT solutions (Thermo Fischer, comprising One Lambda and Life Technologies as well as Abbott Laboratories) also provide SSP products.

Allenex is also working to meet market demand for automated typing solutions, in part through proprietary product development, and in part through partnerships with other companies. Since mid-2011, Allenex is the exclusive global distributor of the HLA typing products SBT Resolver™ and the related software Assign-SBT™ from the Australian company Conexio Genomics. SBT Resolver™ was introduced by Allenex in the second half of 2011. This contract gives Allenex greater opportunity to partner with larger, automated laboratories. Since these laboratories to a large extent strive to use the same supplier for all HLA typing products, this contract will facilitate increased sales opportunities for Allenex SSP products. SBT Resolver™ has been introduced to a large number of potential customers. Following an introductory demonstration, the laboratory usually conducts an independent comparison to the product currently in use. If the comparison favors Allenex, careful product validation is then carried out prior to fully converting to SBT Resolver™.

The validation process tends to be relatively long, usually taking from 6 to 15 months. At the year-end, 34 laboratories had converted, partially or fully, to SBT Resolver™ (17 in North American and 17 in Europa/Asia), with around 20 laboratories at the validation stage.

MARKET PERFORMANCE

Allenex initial strategy has been to introduce SBT Resolver™ to the largest and most automated HLA laboratories in the U.S. and Europe. In the second stage the focus will be on converting mid-sized laboratories from competing products, first through validation and then initiating sales of the product for clinical use at these customers. A number of the largest laboratories have very high volumes as they conduct tests for national or regional typing registers. Major register typing laboratories conduct HLA typing tests on more than 5,000 individuals per year and are very careful in their evaluation of new suppliers.

In the U.S., in particular, there are larger laboratories where SBT typing is used for clinical typing. In total, around 70 of the 200 HLA laboratories use SBT technology clinically, and of these 17 laboratories (around 24 percent) have chosen Allenex as an SBT supplier. Of the 70 laboratories that use SBT technology, around 10 - 15 of them type over 1,500 tissue samples each per year, with a few typing more than that. These are the laboratories that Allenex has initially chosen to focus on, as they hold high value as reference customers, which is important in this segment. Among these large laboratories, Allenex currently has four customers.

The distribution agreement between Conexio Genomics and Allenex subsidiary Olerup SSP AB was extended in June 2014 by two years, now running through April 2018. The agreement with Conexio Genomics, which already comprised the distribution of SBT Resolver™ and the related software Assign-SBT™, also includes two new products for Next Generation Sequencing (NGS), both reagents and software, as well as Gamma Type™, a product for Gamma block typing, an area that has not been possible to analyze previously using traditional methods. Sales of Gamma Type™ is expected to begin in the first quarter 2015 and Allenex plans to successively introduce the NGS portfolio over the next two years. The new products will provide Allenex with further opportunity to reinforce its leading position in the HLA typing market.

PRODUCT DEVELOPMENT

Today, Allenex SSP products have a strong market position in their field of technology. Products are updated on an ongoing basis and the strategy is to offer as close to total solutions as possible. In line with this, continuous product development is carried out, enabling the company to

maintain its market leading position in SSP technology. Allenex continues to develop the existing product line to secure high performance SSP typing. The company is also reviewing solutions adapted for laboratories looking for SSP technology to attain a higher degree of automation, used as a complement to the SSO- and SBT techniques. In 2012, Allenex introduced the Allenex Olerup SSP® Add-ons, as a complement to automated techniques (SSO and SBT). Allenex sees this as a key profile product that expands the company's possibility of using these Add-ons as a complement to competing products/techniques. In 2014, Olerup SSP® introduced more products in this area.

During the year, work began on the development of a new product for HLA typing based on real-time PCR (q-PCR) methodology. The starting point for the development work is SSP technology, which today is at the core of the Allenex product range. The new product will primarily focus on low-resolution typing in conjunction with organ transplantation. In the case of the transplantation of organs from deceased donors it is of great importance to be able to quickly carry out HLA typing to find an appropriate recipient. Real-time PCR is a more automated method that provides faster results with a lesser proportion of manual work. Besides organ transplantation, the method has applications in other types of conditions. It is currently estimated that the new product will be ready for launch in the second half of 2015.

At the initiative of leading transplantation centers, several national and regional clinical trials using the cross-match test XM-ONE®, focused on antibody detection, commenced in 2012 - 2013, both in the U.S. and Europe. These ongoing trials are primarily aimed at further demonstrating the product's clinical value.

SIGNIFICANT EVENTS IN THE GROUP

Significant events in the first quarter

No significant events occurred in the first quarter.

Significant events in the second quarter

- Shares in Allenex previously owned directly by the company's largest shareholder, Mohammed Al Amoudi, have been transferred to a company wholly owned by Mohammed Al Amoudi: Midroc Invest AB. Mohammed Al Amoudi's shares in Xenella Holding AB have also been transferred to Midroc Invest AB.
- Allenex extended and expanded its collaboration with Conexio Genomics and will be launching three new products from Conexio globally.

Significant events in the third quarter

- In 2014, Allenex commenced a major development program aimed at launching diagnostic tests on the

global HLA typing market during 2015 based on real-time PCR methodology.

Significant events in the fourth quarter

No significant events occurred in the fourth quarter.

Significant events after the reporting period

No significant events occurred after the reporting period.

FINANCIAL POSITION, CASH FLOW AND FINANCING

Consolidated operating income for the year rose to SEK 22.9 million (9.6). Other income includes insurance compensation of SEK 1.4 million for goods damaged during shipping, with costs for the discarded goods reported as other expenses. The weakened Swedish krona has had a positive impact on revenues compared to last year as the majority of these are in EUR and USD. At the same time, the weak Swedish currency has had a negative impact on raw material and consumable costs as these are mainly purchased in EUR and USD. Unrealized currency gains are included in other expenses, reducing them by SEK 6.3 million. Unrealized currency gains also improved financial items by SEK 3.4 million. SEK 0.2 million of realized currency losses are included in other expenses.

New product development expenses of SEK 2.8 million were capitalized. The capitalization concerns the development of a new product based on real time PCR (q-PCR), with the launch of the new product expected to start in the second half of 2015.

The group's operations are financed by shareholders' equity and loans. Interest-bearing liabilities amounted to SEK 92.2 million (98.5) primarily secured to finance the acquisition of Olerup SSP and AbSorber. The consolidated equity/assets ratio was 63 percent (63). Consolidated equity was SEK 220.5 million (215.9), equivalent to SEK 1.83 per share (1.79). Cash and cash equivalents totaled SEK 7.3 million (10.0). Cash flow from operating activities before changes in working capital for the year was SEK 10.5 million (-1.6). The increase in inventory is primarily due to the purchase of SBT products before the year-end. Unrealized currency gains of SEK 6.3 million are included in Adjustment for items not included in the cash flow. The Investment activities post includes investments in capitalized assets of SEK 2.8 million and the Financing activities post includes dividends paid to non-controlling interests of SEK 3.7 million as well as amortization of SEK 6.0 million.

RISKS AND UNCERTAINTIES

Allenex has long been a well-established business with well-known products in the field of genomic HLA typing based on

SSP technology, with a significant market share. At the same time, the company faces market risk in the form of competition from other producers, the transition to more automated typing processes as well as new technologies, which may make it difficult for the company to maintain market share and margins.

Operational risk is primarily tied to the company's ability to constantly update its product range and to produce continually updated HLA test kits in pace with market demand.

Products sold and distributed on the basis of cooperation agreements with other companies increase the opportunity of strengthening market position and profitability, while they also carry an increased risk in light of the commitments in terms of resource investments and costs resulting from such agreements. The SBT products from the Australian company Conexio Genomics in particular are expected to achieve significant sales. At the same time, this involves significant competition and market risk. The ability to deliver the right quality on time has both a short and long-term significance for the business. For example, the inability of the partner to deliver due to production downtime could have a substantial negative effect on sales. Allenex has committed to minimum purchasing level from Conexio.

The transplantation test XM-ONE® is primarily established as a research product for larger centers. Work is underway to get the product established in broad clinical use. This has proven to take longer than planned and there is a risk that the product may not attain the success anticipated. This in turn could have a negative on the value of the company's intangible assets and other assets. To date, XM-ONE® is virtually alone in its field and has significant patent protection. However, work is ongoing at the company's competitors to establish similar testing methods. Therefore, there is a risk that the company's competitors may challenge the position that XM-ONE® has on the market.

The Allenex group has a significant exposure to exchange rate fluctuations due to the fact that most of the company's revenues are in EUR and USD, while costs are partly in SEK. This may signify a currency risk for the company. Allenex does not conduct currency hedging activities.

Attracting and maintaining qualified personnel for development, production, marketing, sales, logistics and administration is essential to group performance.

The value of the company is partly dependent on its ability to maintain and protect patents, other intellectual property rights and specific expertise. Patent protection for medical, medtech and biotech products can be uncertain and involve

complex legal and technical issues. Patents must usually be sought and maintained in several jurisdictions, and issued patents may be challenged, invalidated and circumvented. For Allenex or its subsidiaries this may mean loss of or shortened patent protection, which in turn may mean that the company cannot prevent competitors from marketing similar products. The uncertainty associated with patents and patent litigation and other patent processes, may have a negative impact on the competitiveness of Allenex and its subsidiaries, which in turn may have a negative effect on their business.

Both clinical trials and the marketing and sales of products pose a significant risk in terms of product liability. When deemed necessary, the company obtains product liability insurance. No assurance can be given that insurance will cover future claims against Allenex or its subsidiaries.

In certain cases the company is dependent on approval through clinical trials or decisions from public authorities. There are no guarantees that the company will achieve satisfactory results in such trials, or that the required regulatory approval will be granted.

The group's customer relations are stable and long-term, with historically low credit losses. Credit evaluations are carried out on new customers. Credit risk is currently assessed as low, but any change in a negative direction could impact the company's results and financial position.

Part of the financing was raised at variable interest rates, therefore rising interest rates could lead to lower returns for the company, which in turn could affect the company's results and financial position. Based on the current circumstances, the group is of the opinion that it has sufficient liquidity to conduct its operations according to current plans. There is a risk that market conditions and sales will develop negatively, which may have a negative effect on liquidity. The group's ability to refinance maturing loans may also be adversely impacted by group performance and overall conditions in the financial markets. The company's cash and cash equivalents are placed in liquid assets with low credit risk.

No significant changes in risk assessment have been made compared to the annual report 2013.

FINANCIAL INSTRUMENTS

Allenex financial instruments consist of trade account receivable, cash and cash equivalents, trade accounts payable, accrued supplier expenses and interest-bearing liabilities. Liabilities to credit institutions have variable interest rates. Liabilities to shareholders have fixed interest rates, which essentially correspond to current market rates. Other financial assets and liabilities have short life spans. The fair value of all financial instruments is deemed to approximate the book value. Allenex has not netted any

financial assets or liabilities and has not entered into any offset agreements.

RELATED PARTY TRANSACTIONS

Transactions with related parties are detailed in Note 11 of the Allenex 2013 Annual Report. No substantial change has occurred in the content or scope of these transactions for the period.

PARENT COMPANY

Revenues for the year amounted to SEK 2.7 million (3.1). Operating loss for the year was SEK 13.1 million (-13.6). The company's long-term intragroup receivables amounted to SEK 96.0 million (93.1). Cash and cash equivalents were SEK 0.1 million (2.1). The parent company had a negative cash flow from operations of SEK 11.2 million (-14.9). At the year-end, the parent company had 4 (4) employees.

THE SHARE AND SHAREHOLDERS

PRINCIPAL OWNERS 12/31/2014	No. SHARES	OWNERSHIP STAKE %
Midroc Invest AB	43,678,850	36.3
FastPartner AB (publ)	38,886,307	32.3
Xenella Holding AB *)	11,174,755	9.3
Mannersons Fastighets AB	6,774,152	5.6
Avanza Pension	2,263,469	1.9
Nordnet Pensionsförsäkring	654,564	0.5
Handelsbanken fonder	603,937	0.5
Other	16,252,414	13.5
TOTAL	120,288,448	100.0

*) Xenella Holding AB is jointly owned by Midroc Invest AB and FastPartner AB (publ).

ACCOUNTING PRINCIPLES

Allenex applies International Financial Reporting Standards (IFRS) as adopted by the EU and the Swedish Annual Accounts Act. This interim report was prepared in accordance with IAS 34 and the Annual Accounts Act for the group and in accordance with the Annual Accounts Act for the parent company. The accounting principles and methods of calculation applied for the group and the parent company are consistent with those used in the preparation of the most recent Annual Report.

FUTURE REPORT DATES

Interim report January - March: May 20, 2015

Allenex Annual General Meeting: May 20, 2015

Interim report January - June: August 2015

Interim report January - September: November 2015

The Annual General Meeting will be held in Stockholm on May 20, 2015. Shareholders wishing to have matters addressed at the meeting should submit their proposals in writing to the company at the following address: Allenex AB (publ), Attn: AGM 2015, Box 122 83, 102 27 Stockholm or via email to arsstamma@allenex.se. All proposals must be received by Allenex by April 10, 2015 at the latest, or in sufficient time in order to guarantee that their proposals, if required, may be included in the AGM notice.

The Board of Directors proposes that no dividends be paid out for the 2014 financial year.

Stockholm, February 19, 2015

Anders Karlsson

Chief Executive Officer

The information in this interim report is such that Allenex AB (publ) is required to disclose under the Securities Market Act and/or the Financial Instruments Trading Act. This report and earlier financial reports are available at www.allenex.com

This year-end report has not been subject to review by the company's auditors.

This information was released for publication on February 19, 2015 at 14.00 CET

Consolidated statement of comprehensive income		2014	2013	2014	2013
Amount in SEK thousand		OCT-DEC	OCT-DEC	JAN-DEC	JAN-DEC
Net sales		30,695	29,447	125,216	111,811
Changes in inventory of finished goods		5,801	-1,205	5,384	3,163
Capitalized development costs		0	-	711	-
Other revenue		770	922	4,209	3,792
		37,266	29,164	135,520	118,766
Raw materials and consumables		-7,556	-4,405	-26,169	-18,870
Other expenses		-8,080	-10,210	-38,850	-43,740
Cost of employee remuneration		-11,562	-11,790	-45,161	-44,414
Depreciation/amortization		-613	-542	-2,450	-2,151
<i>Operating results</i>		9,455	2,217	22,890	9,591
Results from associated companies		-	-	-	1,705
Other financial expenses and revenues		311	-1,356	-2,520	-5,755
<i>Results after financial items</i>		9,766	861	20,370	5,541
Taxes		-2,615	-707	-5,182	-3,237
<i>Net results for the period</i>		7,151	155	15,188	2,304
Other comprehensive results for the period					
Components that will not be reclassified to net income		-	-	-	-
Components that will be reclassified to net income		-	-	-	-
Translation differences		-2,820	154	-6,850	766
<i>Comprehensive income for the period</i>		4,331	309	8,338	3,070
Results for the period pertaining to:					
Owners of the parent company		5,878	2,321	12,918	5,603
Non-controlling interests		1,273	-2,167	-2,270	-3,299
Comprehensive results for the period pertaining to:					
Owners of the parent company		4,972	2,478	10,228	6,081
Non-controlling interests		-641	-2,169	-1,890	-3,011
Earnings per share, basic and diluted, SEK		0.10	0.02	0.15	0.05
Average number of outstanding shares, basic and diluted		120,288,448	120,288,448	120,288,448	120,288,448
Number of shares at the period end		120,288,448	120,288,448	120,288,448	120,288,448

Consolidated statement of financial position

	2014	2013
Amount in SEK thousand	DEC 31	DEC 31
Assets		
Goodwill	215,272	214,806
Other intangible assets	64,776	63,248
Tangible assets	3,278	3,781
Deferred tax assets	4,170	7,077
<i>Total non-current assets</i>	287,496	288,912
Inventories	38,106	29,733
Current receivables	17,002	15,492
Cash and cash equivalents	7,323	10,046
<i>Total current assets</i>	62,431	55,271
Total assets	349,927	344,183
Equity and liabilities		
Equity	220,480	215,859
Interest-bearing non-current liabilities	71,324	82,874
Deferred tax liabilities	14,321	13,446
Interest-bearing non-current liabilities	20,923	14,926
Non-interest bearing current liabilities	22,879	17,078
Total equity and liabilities	349,927	344,183

Consolidated statement of changes in equity

	2014	2013
Amount in SEK thousand	DEC 31	DEC 31
Opening balance	215,859	216,196
Dividends paid to non-controlling interests	-3,717	-3,407
Comprehensive results for the year	8,338	3,070
<i>Closing balance</i>	220,480	215,859
Of which pertaining to:		
Owners of the parent company	231,210	224,699
Non-controlling interests	-10,730	-8,840

Consolidated statement of cash flows

	2014	2013
Amount in SEK thousand	JAN-DEC	JAN-DEC
Operating income	22,890	9,591
Adjustment for items not included in the cash flow	-3,832	2,678
Financial items	-3,012	-4,465
Taxes paid	-504	-1,328
<i>Cash flow from operations before changes in working capital</i>	15,542	6,476
Increase (-)/Decrease(+) in inventories	-6,950	-7,825
Increase (-)/Decrease(+) in operating receivables	1,072	-2,147
Increase (-)/Decrease(+) in operating liabilities	802	1,905
<i>Cash flow from operating activities</i>	10,466	-1,591
Cash flow from investing activities	-3,235	1,237
Cash flow from financing activities	-9,717	-3,874
Cash flow for the year	-2,486	-4,228
Cash and cash equivalents at the start of the year	10,046	14,327
Exchange rate differences in cash and cash equivalents	-237	-53
<i>Cash and cash equivalents at the year-end</i>	7,323	10,046

Parent company income statement

	2014		2013	
	OCT-DEC	OCT-DEC	JAN-DEC	JAN-DEC
Amount in SEK thousand				
Revenues	687	925	2,749	3,142
Other external costs	-2,301	-2,108	-7,738	-9,211
Personnel costs	-1,120	-1,949	-7,958	-7,421
Depreciation/amortization	-28	-31	-109	-141
<i>Operating results</i>	<i>-2,762</i>	<i>-3,163</i>	<i>-13,056</i>	<i>-13,631</i>
Results from associated companies	-	-	-	1,705
Other financial expenses and revenues	-550	-435	-778	-822
<i>Results after financial items</i>	<i>-3,312</i>	<i>-3,598</i>	<i>-13,834</i>	<i>-12,748</i>
Appropriations				
Group contributions received	38,355	32,628	38,355	32,628
Group contributions paid	-17,158	-25,721	-17,158	-25,721
<i>Results before tax</i>	<i>17,885</i>	<i>3,309</i>	<i>7,363</i>	<i>-5,841</i>
Taxes	0	0	0	0
<i>Results for the period</i>	<i>17,885</i>	<i>3,309</i>	<i>7,363</i>	<i>-5,841</i>

Parent company statement of comprehensive income

Results for the period	17,885	3,309	7,363	-5,841
Other comprehensive results for the period	-	-	-	-
<i>Comprehensive results for the period</i>	<i>17,885</i>	<i>3,309</i>	<i>7,363</i>	<i>-5,841</i>

Parent company balance sheet

	2014		2013	
	DEC 31		DEC 31	
Amount in SEK thousand				
Assets				
Tangible assets		150		217
Shares in subsidiaries		57,378		57,378
Non-current intra-group receivables		96,003		93,102
Deferred tax assets		1,626		1,626
<i>Total non-current assets</i>		<i>155,157</i>		<i>152,323</i>
Current receivables		73,944		54,505
Cash and bank		91		2,118
<i>Total current assets</i>		<i>74,035</i>		<i>56,623</i>
Total assets		229,192		208,946
Equity and liabilities				
Equity		165,143		157,780
Non-current liabilities		19,609		19,349
Current liabilities		44,440		31,817
<i>Total equity and liabilities</i>		<i>229,192</i>		<i>208,946</i>
Changes in equity, parent company				
Opening balance		157,780		163,621
Results for the year		7,363		-5,841
Closing balance		165,143		157,780

Parent company statement of cash flows

	2014	2013
Amount in SEK thousand	JAN-DEC	JAN-DEC
Operating results	-13,056	-13,631
Adjustments for items not included in the cash flow	109	141
Financial items	12	-999
<i>Cash flow from operating activities before changes in working capital</i>	-12,935	-14,489
Increase (-)/Decrease(+) in operating receivables	1,815	-111
Increase (-)/Decrease(+) in operating liabilities	-85	-251
<i>Cash flow from operating activities</i>	-11,205	-14,851
Cash flow from investing activities	9,178	22,489
Cash flow from financing activities	0	-11,000
Cash flow for the year	-2,027	-3,362
Cash and cash equivalents at the start of the year	2,118	5,480
<i>Cash and cash equivalents at the year-end</i>	91	2,118

KEY FIGURES

	2014	2013
	JAN-DEC	JAN-DEC
Net sales, SEK thousand	125,216	111,811
Operating income, SEK thousand	22,890	9,591
Earnings after tax, SEK thousand	15,188	2,304
Earnings per share, basic and diluted, SEK	0.11	0.05
Equity per share, SEK	1.83	1.79
Equity/assets ratio, %	63	63
Return on equity, %	8	2
Average number of employees	55	55
Number of shares outstanding at the period-end	120,288,448	120,288,448
Average number of shares outstanding	120,288,448	120,288,448
Share price at the year-end, SEK	1.92	2.42
Market cap, SEK thousand	230,954	291,098

Definitions:

Earnings per share	Earnings after tax attributable to the parent company divided by the average number of outstanding shares.
Equity per share	Equity divided by the number of outstanding shares at the period end.
Equity/assets ratio	Equity at the year-end in relation to total assets.
Return on equity	Results attributable to parent company shareholders divided by equity attributable to the owners of the parent.
Operating margin	Earnings before financial items divided by net sales

For a more detailed list see annual report 2013, page 62

Companies in the Allenex group

PRODUCTION AND R&D COMPANIES



Olerup SSP AB is world leading in the development of kits for genomic HLA typing, based on SSP technology. The product is used prior to a transplantation to match the donor and recipient. The better the match the lower the risk of complications following transplantation. HLA typing is a standard procedure prior to bone marrow transplantation (hematopoietic stem cell transplantation) and is also used in conjunction with organ transplants (kidney, lung, heart, etc.). In 2011, Olerup SSP entered into a five-year exclusive global agreement (excl. Australia, New Zealand and Taiwan) with Conexio Genomics, Perth, Australia. In 2014, the agreement was extended to April 2018. Allenex ownership stake in Olerup SSP AB is 91 percent. For more information visit www.olerup-ssp.com



AbSorber develops products that facilitate successful transplantation. AbSorber's transplantation test XM-ONE®, identifies antibodies that play a key role in rejection reactions. The company's research portfolio also includes a patented ABO column for transplantations between people of different blood groups and an ABO diagnostic test that measures the occurrence of blood group antibodies. Allenex ownership stake of AbSorber is 98 percent. For more information visit www.absorber.se

SALES AND DISTRIBUTION COMPANIES



Olerup GmbH, based in Vienna, is responsible for sales, distribution and logistics in Europe and the rest of the world excluding North, Central and South America as well as the Nordic region. Sales encompass Olerup SSP's HLA typing products and AbSorber's XM-ONE® transplantation test. Furthermore, from mid-year 2011, the company also sells and distributes products from the Australian company Conexio Genomics. Sales are conducted by a proprietary sales team in Germany, Austria, Belgium, the Netherlands and Slovenia. Sales in other markets are handled by distributors. The company is owned by Olerup International, in which Allenex has an ownership stake of 75 percent. For more information visit www.olerup.com



Olerup Inc., domiciled in West Chester, PA, USA, is responsible for the sales, distribution and logistics of Olerup SSP and AbSorber products. Furthermore, since mid-2011, the company sells and distributes products from the Australian company Conexio Genomics. The company has its own sales organization in the US, while sales in Canada and Central and South America are handled by distributors. AbSorber owns 50 percent of the company. For more information visit www.olerup.com